1534: Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP.
Time to disease-related pain and first opioid use in patients with metastatic
castration-resistant prostate cancer treated with sipuleucel-T. Prostate Cancer
Prostatic Dis. 2014 Sep;17(3):259-64. doi: 10.1038/pcan.2014.21. Epub 2014 Jun
24. PubMed PMID: 24957547; PubMed Central PMCID: PMC4160816.


1535: Small EJ, Fong L. Developing immunotherapy as legitimate therapy for
patients with prostate cancer. J Clin Oncol. 2010 Mar 1;28(7):1085-7. doi:
10.1200/JCO.2009.26.3483. Epub 2010 Jan 25. PubMed PMID: 20100956.


1536: Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, Nelson WG,
Ando D, Howard C, Borellini F, Nguyen M, Hege K, Simons JW. Granulocyte
macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy
for hormone-refractory prostate cancer. Clin Cancer Res. 2007 Jul
1;13(13):3883-91. PubMed PMID: 17606721.


1537: Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH,
Verjee SS, Jones LA, Hershberg RM. Placebo-controlled phase III trial of
immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic,
asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul
1;24(19):3089-94. PubMed PMID: 16809734.


1538: Small EJ. Monoclonal antibody therapy for prostate cancer: finally a
reality? J Clin Oncol. 2004 Jul 1;22(13):2515-6. Epub 2004 Jun 1. PubMed PMID:
15173211.


1539: Small EJ, Reese DM. New treatment strategies in advanced prostate cancer.
Radiol Clin North Am. 2000 Jan;38(1):203-11, ix-x. Review. PubMed PMID: 10664673.


1540: Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, Valone FH.
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic
cells. J Clin Oncol. 2000 Dec 1;18(23):3894-903. PubMed PMID: 11099318.